Skip to main content

RDY · Dr Reddys Laboratories Ltd

Track RDY — free
$14.89 +0.06 (+0.40%) At close · Nov 20
Market Cap
$12.41B
Shares
833.66M
Volume · Nov 20 1.75M Avg daily vol (3M) 2.84M

Price & Indicators

 

Key stats

Close
$14.89
Fri 20 Nov
Open
$14.88
Fri 20 Nov
Average volume, 30 days
2.7M
shares a session
Short interest
25.3M
3.0% of shares · 7.8 days to cover
Day range
$14.86$15.10
Open $14.88 Close $14.89
52-week closing range
$11.38$15.38
Close $14.89 3.2% under the high
Short volume, last session
59%
Last earnings
Oct 23, 2026
Price history
Jan 2020 to Nov 2026

Up next

Jan 20, 2027 Est · unconfirmed · in 9 wks

Latest documents

2026
Nov 16
Current report 6-K
USFDA closes Hyderabad inspection as Voluntary Action Indicated

The USFDA classified the GMP inspection of Dr. Reddy’s Laboratories Limited’s formulations manufacturing facility FTO-3 in Bachupally, Hyderabad, as ‘Voluntary Action Indicated (VAI)’ and officially closed it under 21 CFR 20.64(d)(3).

3 source passages
This is in reference to our intimation dated August 14, 2026, wherein we had informed regarding the Good Manufacturing Practices (GMP) inspection conducted by the United States Food & Drug Administration (USFDA) at our formulations manufacturing facility (FTO-3) in Bachupally, Hyderabad. We wish to inform you that the USFDA has classified the inspection outcome as ‘Voluntary Action Indicated (VAI)’ and concluded that the inspection is officially closed under 21 CFR 20.64(d)(3). For Dr. Reddy’s Laboratories Limited Open the document at this passage
Nov 10
Current report 6-K
Investor meetings scheduled in Mumbai and London

Dr. Reddy’s Laboratories Limited said management will hold in-person group meetings with institutional investors in Mumbai on 16.11.2026 and London on 17.11.2026 – 18.11.2026.

4 source passages
This is to inform that the Company’s management will be participating in the following investor conference with single institution(s)/ investor groups: 16.11.2026 | JM Financial | Mumbai | In-Person | Group Meet | 10:00 - 17:00 IST 17.11.2026 – 18.11.2026 | Investec | London | In-Person | Group Meet | 09:00 - 17:00 GMT For Dr. Reddy’s Laboratories Limited Open the document at this passage
Nov 5
Current report 6-K
ANVISA authorizes generic semaglutide injection in Brazil

Dr. Reddy’s Laboratories Ltd. said Brazil’s National Health Surveillance Agency (ANVISA) granted marketing authorization for generic semaglutide injection for adults with insufficiently controlled type 2 diabetes mellitus. The company plans to launch the once-weekly treatment in Brazil with Aché.

2 source passages
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY), along with its subsidiaries together referred to as “Dr. Reddy’s”, today announced that Brazil’s National Health Surveillance Agency (ANVISA) has granted marketing authorization for generic semaglutide injection for the treatment of adults with insufficiently controlled type 2 diabetes mellitus, as an adjunct to diet and exercise, either as monotherapy when metformin is considered inappropriate due to intolerance or contraindications, or in addition to other medicinal products for the treatment of diabetes. We plan to launch semaglutide in Brazil with Aché. Open the document at this passage
Nov 4
Current report 6-K
5,91,270 Equity Shares Allotted to Employees

Dr. Reddy’s Laboratories Limited allotted 5,91,270 fully paid equity shares of Re.1/- each on November 4, 2026 to eligible employees exercising options under Dr. Reddy’s Employees ADR Stock Options Scheme, 2007.

Source passage
This is to inform you that the Company has allotted 5,91,270 equity shares of Re.1/- each of the Company, fully paid up, on November 4, 2026, to eligible employees pursuant to exercise of their Stock Options under Dr. Reddy’s Employees ADR Stock Options Scheme, 2007. Open the document at this passage
Oct 29
Current report 6-K
Transcript covers quarter and half year ended September 30, 2026

Dr. Reddy’s Laboratories Limited furnished the earnings call transcript for the quarter and half year ended September 30, 2026, following the October 23, 2026 call.

2 source passages
For Dr. Reddy’s Laboratories Limited Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the transcript of the Earnings call for the quarter and half year ended September 30, 2026, conducted on October 23, 2026. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
+3.2%
Year over year
Operating margin
15.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
0.6%
Trailing 12 months
Shares change YoY
+0.0%
Year over year · more shares
Price change (1Y)
+7.1%
Trailing year
Short interest
3.0%
Latest settlement · 7.8 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Limited Quant / Vol Low
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Buy
50 / 200-day cross Golden cross
Price vs 200-day avg +12%
above
Price vs 50-day avg +12%
above
RSI (14) 68
neutral
MACD trend Negative
52-week position 88%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +13%
trailing
6-month return +14%
trailing
YTD return +6%
this year
Relative strength +23%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) Golden cross
50d $13 › 200d $13 — 50d above 200d
Institutional flow Distributing
-2% holders QoQ · +25 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
3.03% of shares out · ▼ -3.2% MoM · 7.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
237 holders — mid 3-yr range
Squeeze score 65
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Low
Volatility 27%
annualized · 1-yr
Max drawdown −26%
past year
ATR 1.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Jun 30, 2020
Effective tax rate · full year 25% – 27%
Previous outlook earlier release · from the Earnings Call filed Mar 31, 2020

Still-open targets the latest release did not restate under the same label.

Gross margin · normal expectation range 52% – 54%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 2 · 4
50 / 200-day cross
Golden cross Bullish
Price vs 200-day avg
+12% Bullish
Price vs 50-day avg
+12% Bullish
RSI (14)
68 Neutral
MACD trend
Negative Bearish
52-week position
88% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) Golden cross
50d $13 › 200d $13 — 50d above 200d
Institutional flow Distributing
-2% holders QoQ · +25 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
3.03% of shares out · ▼ -3.2% MoM · 7.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
237 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $11 Now $15 · 88% Range high $15
vs 200-day avg +12% vs 50-day avg +12% 50-day above 200-day golden cross

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
RDY
Dr Reddys Laboratories Ltd
this stock
$12.41B +6.1% — — 3.0%
TAK
Takeda Pharmaceutical Co Ltd
$69.55B +39.6% — — 0.1%
GALDY
Galderma Group AG
$50.29B +4.1% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
$45.77B +25.7% +4.3% 89.2 2.4%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
$40.66B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
237
% held
15.4%
Net QoQ
+2.9M sh
Top holder
MORGAN STANLEY
Held Float
View
Held by Funds
Fund positions
63
View
Short & Settlement
Short Interest Falling
Shares short
25.3M
Days to cover
7.8d
Change
-843.3K sh
View
Short Volume
Short vol %
59%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
550.1K
Value
$7.8M
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
40.2%
Week of
Oct 12, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
6-K
Filed
Nov 16, 2026
This year
106

The USFDA classified the GMP inspection of Dr. Reddy’s Laboratories Limited’s formulations manufacturing facility FTO-3 in Bachupally, Hyderabad, as ‘Voluntary Action Indicated (VAI)’ and officially closed it under 21 CFR 20.64(d)(3).

View
Proposed Sales
Value
$5.4M
Shares
65.5K
Filed
Jul 29, 2024
View
Earnings & Events
Webcasts
Last webcast
Oct 23, 2026
View

Performance

5D 20D 120D MTD YTD
RDY +1.0% +12.7% +14.3% +5.1% +6.1%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY +9.6% +22.0% +23.5% +13.8% +4.9%

Capital returns

Latest dividend
$0.083 / share · ex Jul 24, 2026
Cut 8.8%
Paid (TTM)
$0.083 / share · 1 payout
Dividend yield (TTM, derived)
— · history filling in
Full dividend history

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1135951 CUSIP 256135203 13F (30d) 236 filings 207 filers Visit website Investor relations